LifeMD (NASDAQ:LFMD) Price Target Raised to $15.00

LifeMD (NASDAQ:LFMD - Free Report) had its target price upped by Cantor Fitzgerald from $13.00 to $15.00 in a report released on Thursday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other brokerages have also issued reports on LFMD. HC Wainwright raised their target price on shares of LifeMD from $10.00 to $12.00 and gave the stock a buy rating in a research report on Thursday, January 11th. BTIG Research increased their price target on LifeMD from $13.00 to $14.00 and gave the company a buy rating in a research note on Tuesday, April 23rd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of Buy and a consensus price target of $11.60.

LifeMD Price Performance

Shares of LFMD traded down $3.03 during trading hours on Thursday, hitting $9.30. 3,489,623 shares of the company were exchanged, compared to its average volume of 839,018. The company has a quick ratio of 1.15, a current ratio of 1.22 and a debt-to-equity ratio of 3.22. The company has a market cap of $380.28 million, a price-to-earnings ratio of -13.64 and a beta of 1.38. LifeMD has a fifty-two week low of $1.66 and a fifty-two week high of $12.88. The firm's fifty day moving average is $10.18 and its 200 day moving average is $8.08.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its earnings results on Monday, March 11th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The firm had revenue of $44.86 million during the quarter, compared to analysts' expectations of $40.65 million. On average, equities analysts anticipate that LifeMD will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LifeMD

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LFMD. Tower Research Capital LLC TRC lifted its holdings in shares of LifeMD by 266.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company's stock valued at $38,000 after acquiring an additional 3,348 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of LifeMD by 24.8% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 25,200 shares of the company's stock valued at $158,000 after purchasing an additional 5,000 shares in the last quarter. Dorsey Wright & Associates bought a new stake in LifeMD in the third quarter worth about $37,000. Worth Venture Partners LLC acquired a new stake in shares of LifeMD in the third quarter worth $64,000. Finally, Freedom Wealth Alliance LLC acquired a new position in shares of LifeMD during the 3rd quarter worth about $68,000. 35.52% of the stock is currently owned by institutional investors.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.